Introducing cell line identification to the Euretos Platform

We are very excited to announce the launch of our latest workflow which enables users to find cell lines based on gene expression levels. This workflow significantly accelerates translational research, saving time and costs and improving in-vitro experiment design, disease modeling, biomarker & target discovery and drug screening efficiency. 

The workflow enables researchers to identify cell lines with specific gene expression profiles, enabling more precise modeling of diseases, in particular for cancers. Expression data is from CCLE (RNA and protein expression) and Cell Model Passports (protein expression only). Cell lines can be included or excluded from the ranking individually or per tumor type. 

Searching for cell lines with desired gene expression levels manually is time-consuming and resource-intensive. The workflow significantly reduces the time and resources spent on this task, allowing researchers to focus on their experimental work and analysis. It provides many benefits in both basic disease research and drug discovery such as:

• Enhanced Disease Modeling: Accurate cell line selection can improve the modeling of diseases at the molecular level, leading to a deeper understanding of disease mechanisms, progression, and heterogeneity. 
  
  
• Genetic and Molecular Insights: The workflow enables researchers to dissect the roles of specific genes and their expression patterns in disease contexts, facilitating the discovery of novel genetic pathways and interactions that could be potential therapeutic targets.
  
  
• Identification of Biomarkers: By studying cell lines that accurately express specific genes associated with diseases, researchers can identify potential biomarkers for disease detection, progression, and prognosis.
  
  
• Target Identification and Validation: by using cell lines with specific gene expression profiles, researchers can more effectively identify and validate new therapeutic targets. This step is crucial in the early stages of drug discovery, setting the foundation for the development of targeted therapies.
  
  
• High-Throughput Screening (HTS): Cell lines expressing relevant genes can be utilized in HTS to evaluate thousands of compounds, identifying those with potential therapeutic effects. This process is essential for narrowing down candidates for further development.
  
  
• Mechanism of Action Studies: Understanding how a drug exerts its effects is crucial for further development and regulatory approval. Cell lines with defined gene expression profiles can help elucidate the mechanisms through which compounds modulate disease pathways.
  
  
• Safety Assessment: Early assessment of compound safety is vital in drug development. Specific cell lines can be used to predict cytotoxic effects and potential off-target effects, reducing the likelihood of adverse outcomes in later stages.

In summary, this new workflow offers distinct benefits across all the stages of translational research. In basic/fundamental disease research, it enhances disease understanding and biomarker identification. In drug discovery, it streamlines target identification, compound screening, and optimization processes, ultimately contributing to the development of safer, more effective therapies.